Table 3.

The enrichment analysis of candidate targets of quercetin.

Type	Term	Gene count	P-value
GO	GO-BP:positive regulation of transcription from RNA polymerase II promoter	38	1.26E-16
	GO-BP:positive regulation of transcription, DNA-templated	27	1.31E-14
	GO-BP:response to drug	25	6.40E-18
	GO-BP:inflammatory response	22	1.04E-12
	GO-BP:signal transduction	22	1.79E-04
	GO-BP:positive regulation of gene expression	20	1.17E-13
	GO-BP:negative regulation of cell proliferation	19	1.23E-09
	GO-BP:apoptotic process	18	1.44E-06
	GO-BP:negative regulation of transcription from RNA polymerase II promoter	18	3.32E-05
	GO-BP:oxidation–reduction process	17	1.12E-05
	GO-MF:protein binding	102	1.06E-10
	GO-MF:identical protein binding	29	1.31E-12
	GO-MF:enzyme binding	25	3.80E-17
	GO-MF:transcription factor activity, sequence-specific DNA binding	23	2.66E-06
	GO-MF:DNA binding	23	0.0066762
	GO-MF:protein homodimerization activity	22	1.16E-07
	GO-MF:transcription factor binding	19	4.28E-12
	GO-MF:ATP binding	19	0.0310054
	GO-MF:sequence-specific DNA binding	18	3.44E-07
	GO-MF:protein heterodimerization activity	16	2.20E-06
KEGG	KEGG:Pathways in cancer	42	3.31E-23
	KEGG:Hepatitis B	27	1.44E-20
	KEGG:PI3K-Akt signaling pathway	25	1.06E-09
	KEGG:HTLV-I infection	23	8.94E-11
	KEGG:Proteoglycans in cancer	22	6.43E-12
	KEGG:MAPK signaling pathway	21	3.60E-09
	KEGG:MicroRNAs in cancer	21	2.95E-08
	KEGG:HIF-1 signaling pathway	20	4.96E-16
	KEGG:TNF signaling pathway	20	4.34E-15
	KEGG:Influenza A	20	3.66E-11